Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Opinion on Drug Safety

• Publication date

  2016-04-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14740338.2016.1165668PMID 26967126
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.

  2015cited by this paper
• Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial

  2015cited by this paper
• The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.

  2015cited by this paper
• Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.

  2015cited by this paper
• A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.

  2015cited by this paper
• Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.

  2015cited by this paper
• Augmentation of Clozapine With Ziprasidone in Refractory Schizophrenia: A Double-Blind, Placebo-Controlled Study

  2014cited by this paper
• Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.

  2014cited by this paper
• Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients.

  2013cited by this paper
• Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone

  2013cited by this paper
• The Clinical Efficiency of Aripiprazole with Clozapine for the Female Refractory Schizophrenia

  2013cited by this paper
• Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia.

  2013cited by this paper
• Metabolic effects of adjunctive aripiprazole in clozapine‐treated patients with schizophrenia

  2013cited by this paper
• Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study

  2013cited by this paper
• Augmenting Clozapine With Sertindole: A Double-Blind, Randomized, Placebo-Controlled Study

  2012cited by this paper
• Augmentation of clozapine with a second antipsychotic – a meta‐analysis

  2012cited by this paper
• The study of combining Clozapine and Aripiprazole for the treatment of negative symptoms of schizophrenia

  2012cited by this paper
• Effect of combined low-dose clozapine and ziprasidone on treatment of refractory schizophrenia

  2012cited by this paper
• Safety and tolerability of antipsychotic polypharmacy

  2012cited by this paper
• Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.

  2012cited by this paper
• Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

  2012cited by this paper
• Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients

  2012cited by this paper
• Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis

  2012cited by this paper
• A Clinical Control Study on Effects of Clozapine with Risperidone on Refractory Schizophrenia

  2012cited by this paper
• Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

  2012cited by this paper
• Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

  2012cited by this paper
• Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy

  2011cited by this paper
• Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

  2011cited by this paper
• Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study

  2011cited by this paper
• Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

  2011cited by this paper
• 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)

  2011cited by this paper
• Comparative Study on Risperidone Combined Clozapine and Risperidone in the Treatment of Refractory Schizophrenia

  2011cited by this paper
• Risperidone and low dose Clozapine combination for the treament of male refractory schizophrenia

  2011cited by this paper
• Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior.

  2011cited by this paper
• Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.

  2010cited by this paper
• Clinical observation of olanzapine combined with sulpiride in refractory schizophrenia

  2010cited by this paper
• A Randomized, Double-Blind Comparison of Risperidone Versus Low-Dose Risperidone Plus Low-Dose Haloperidol in Treating Schizophrenia

  2010cited by this paper
• Adjunctive Risperidone for Partially Responsive People with Schizophrenia Treated with Clozapine

  2010cited by this paper
• Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications

  2010cited by this paper
• The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

  2010cited by this paper
• Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.

  2010cited by this paper
• From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

  2010cited by this paper
• Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.

  2010cited by this paper
• International consensus study of antipsychotic dosing.

  2010cited by this paper
• Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients

  2009cited by this paper
• 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

  2009cited by this paper
• A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

  2009cited by this paper
• Does the addition of a second antipsychotic drug improve clozapine treatment?

  2009cited by this paper
• Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

  2009cited by this paper
• Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.

  2009cited by this paper
• Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

  2008cited by this paper
• Comprar Stahl's Essential Psychopharmacology. Neuroscientific Basis and Practical Applications | Stephen M. Stahl | 9780521857024 | Cambridge University Press

  2008cited by this paper
• Cost of antipsychotic polypharmacy in the treatment of schizophrenia

  2008cited by this paper
• Change in sexual dysfunction with aripiprazole: a switching or add-on study

  2008cited by this paper
• Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.

  2008cited by this paper
• Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

  2007cited by this paper
• Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.

  2007cited by this paper
• Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder*

  2007cited by this paper
• Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

  2007cited by this paper
• Balancing Efficacy and Safety in Treatment with Antipsychotics

  2007cited by this paper
• Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

  2006cited by this paper
• An exploratory open‐label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia

  2006cited by this paper
• Schizophrenia, neuroleptic medication and mortality

  2006cited by this paper
• Clozapine alone versus clozapine and risperidone for refractory schizophrenia.

  2006cited by this paper
• Clozapine alone versus clozapine and risperidone with refractory schizophrenia.

  2006cited by this paper
• Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

  2005cited by this paper
• Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.

  2005cited by this paper
• Normalization of risperidone-induced hyperprolactinemia with the addition of aripiprazole.

  2005cited by this paper
• Clinical controlled studies of olanzapine combined with sulpiride therapy in refractory schizophrenia

  2005cited by this paper
• A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

  2005cited by this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia

  2005cited by this paper
• Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology

  2004cited by this paper
• Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

  2004cited by this paper
• Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

  2004cited by this paper
• Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia

  2004cited by this paper
• Antipsychotic polypharmacy.

  2004cited by this paper
• The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

  2004cited by this paper
• Combination antipsychotic therapy in clinical practice.

  2003cited by this paper
• Combination antipsychotic therapy in clinical practice.

  2003cited by this paper
• Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.

  2002cited by this paper
• Blinding in randomised trials: hiding who got what.

  2002cited by this paper
• A Control Study of Risperidone in Combination with Clozapine in Treating Refractory Schizophrenia

  2001cited by this paper
• A Nonparametric “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis

  2000cited by this paper
• Mortality in schizophrenia

  1998cited by this paper
• Practice guideline for the treatment of patients with schizophrenia

  1997cited by this paper
• Sulpiride augmentation in people with schizophrenia partially responsive to clozapine

  1997cited by this paper
• Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.

  1995cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• ARE TRANQUILIZER COMBINATIONS MORE EFFECTIVE THAN A SINGLE TRANQUILIZER?

  1964cited by this paper
• Study of the differential behavioral effects of reserpine, chlorpromazine, and a combination of these drugs in chronic schizophrenic patients.

  1957cited by this paper
• Blinding in randomised trials : hiding who got what

  year unknowncited by this paper

• Prescription des antipsychotiques

  2025cites this paper
• Effectiveness of a multidisciplinary outreach intervention for individuals with severe mental illness in supported accommodation

  2025cites this paper
• Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment

  2025cites this paper
• La prescription de médicaments psychotropes chez l’enfant et l’adolescent en France : caractéristiques et évolution entre 2010 et 2023

  2025cites this paper
• Guideline for pharmacological treatment of schizophrenia 2022

  2024cites this paper
• [Metabolic syndrome and antipsychotic therapy of schizophrenia].

  2024cites this paper
• Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink

  2023cites this paper
• Co-prescription of aripiprazole on prolactin levels in long-term hospitalized chronic schizophrenic patients with co-morbid type 2 diabetes: A retrospective clinical study

  2023cites this paper
• The promise and pitfalls of antipsychotic co-initiation in schizophrenia.

  2022cites this paper
• Should Antipsychotic Polypharmacy Be Used for Patients with Schizophrenia and Related Psychoses?

  2021cites this paper
• Should Antipsychotic Polypharmacy Be Used for Patients with Schizophrenia and Related Psychoses?

  2021cites this paper
• The risk for Torsades de Pointes and polypharmacy in schizophrenia.

  2021cites this paper
• Antipsychotika

  2020cites this paper
• Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?

  2020cites this paper
• Long-term clinical efficacy of maintenance electroconvulsive therapy in patients with treatment-resistant schizophrenia on clozapine.

  2019cites this paper
• Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.

  2019cites this paper
• Antipsychotika

  2019cites this paper
• Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia

  2019cites this paper
• Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia – a pooled analysis

  2019cites this paper
• Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy.

  2019cites this paper
• Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?

  2019cites this paper
• Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.

  2018cites this paper
• Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment

  2018cites this paper
• Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews

  2018influential citation
• Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study

  2017cites this paper
• Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents

  2017cites this paper
• A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia.

  2017cites this paper
• Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loop.

  2017cites this paper
• Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

  2017cites this paper
• Non‐clozapine antipsychotic combinations for treatment‐resistant schizophrenia

  2017cites this paper
• Appendix A: Summary of evidence from surveillance

  2017cites this paper
• The Relationship between Psychotropic Drug Use and Suicidal Behavior in Japan: Japanese Adverse Drug Event Report

  2016cites this paper
• Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions.

  2016cites this paper
• Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 2: Nonpharmacological Interventions.

  2016cites this paper
• Cognitive behavioural therapy for auditory hallucinations in schizophrenia: A review

  2016cites this paper